Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884451075
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.55 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 0.71 | |||||
Debt-to-EBITDA | -1.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.82 | |||||
Beneish M-Score | -1.12 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -38.5 | |||||
3-Year EBITDA Growth Rate | 3.4 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | -24.4 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.32 | |||||
9-Day RSI | 29.17 | |||||
14-Day RSI | 31.84 | |||||
6-1 Month Momentum % | 33.58 | |||||
12-1 Month Momentum % | 16.95 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.18 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 0.92 | |||||
Days Sales Outstanding | 139.97 | |||||
Days Payable | 1086.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -109.2 | |||||
Shareholder Yield % | -7.68 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.28 | |||||
Operating Margin % | -180.63 | |||||
Net Margin % | -167.69 | |||||
FCF Margin % | -123.28 | |||||
ROE % | -66.86 | |||||
ROA % | -36.05 | |||||
ROIC % | -112.22 | |||||
ROC (Joel Greenblatt) % | -2862.25 | |||||
ROCE % | -44.78 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.19 | |||||
PB Ratio | 3.06 | |||||
EV-to-EBIT | -3.77 | |||||
EV-to-Forward-EBIT | -2.97 | |||||
EV-to-EBITDA | -3.85 | |||||
EV-to-Forward-EBITDA | -3.38 | |||||
EV-to-Revenue | 6.1 | |||||
EV-to-Forward-Revenue | 5.29 | |||||
EV-to-FCF | -4.92 | |||||
Earnings Yield (Greenblatt) % | -26.56 | |||||
FCF Yield % | -17.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Zevra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 25.34 | ||
EPS (TTM) (€) | -1.198 | ||
Beta | 0.66 | ||
Volatility % | 44.25 | ||
14-Day RSI | 31.84 | ||
14-Day ATR (€) | 0.084334 | ||
20-Day SMA (€) | 4.36 | ||
12-1 Month Momentum % | 16.95 | ||
52-Week Range (€) | 3.82 - 6.45 | ||
Shares Outstanding (Mil) | 41.85 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Zevra Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Zevra Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Zevra Therapeutics Inc Frequently Asked Questions
What is Zevra Therapeutics Inc(FRA:1GDA)'s stock price today?
When is next earnings date of Zevra Therapeutics Inc(FRA:1GDA)?
Does Zevra Therapeutics Inc(FRA:1GDA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |